The results of the exploratory analysis from POSEIDON trial were presented by Dr. Melissa Johnson. In this phase III trial,...

ADT Intensification might be the resort to delay biochemical progression in High risk biochemical relapse (BCR) #prostate cancer after Radical...

In a striking result presented at the ASTRO 2022 meeting, a randomized Phase II Trial have shown a survival benefit...

Perioperative #nivolumab did not improve relapse free survival (RFS) in early stage #RCC. This was illustrated in phase III PROSPER...

First results of the RADICALS-HD trial presented by Dr. Chris Parker demonstrated that in patients having post-operative radiotherapy after...

In the non-inferiority, RATIONALE-301 study presented by Dr. Masatoshi Kudo, Single agent Tislelizumab (TIS), an anti-PD-1 monoclonal antibody, showed comparable...

In the updated analysis of phase III RESONATE-2 trial, treatment with BTK inhibitor (#ibrutinib) for at least 5 years showed...

The combination of ribociclib and endocrine therapy improved PFS in the first-line setting for premenopausal patients with aggressive ER-positive, HER2-negative...

The addition of stereotactic body radiation therapy (SBRT) to sorafenib for patients with hepatocellular carcinoma (HCC) improved PFS and OS...

In the phase II trial RTOG1205, Reirradiation (re-RT) with concurrent bevacizumab (BEV) demonstrated a clinically meaningful improvement in PFS in...